|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||14.83 / 63.73|
Large pharmaceutical companies could be interested in buying the drug company, but even if a deal isn't forthcoming an activist investor could seek to elect directors and make one happen
Small caps are down 0.12% despite the strength in the Nasdaq ETF.
Sarepta CEO Ed Kaye said he's stepping down.
Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.
The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
These heavily shorted stocks could get squeezed sharply higher if they report positive earnings this week.
Sarepta Therapeutics, Paratek Pharmaceuticals and PDL BioPharma were among the biotech stock movers in premarket trading on Monday.
If you aren't positioned long already, you are struggling with what to do here.
This is one of those days when it may pay to walk away.
Sarepta Therapeutics, Bellicum Pharmaceuticals and Novavax were among the biotech stock movers in premarket trading on Wednesday.
Keep an eye on the pattern of morning weakness and afternoon strength.
After yesterday's surprise pullback, this is the sort of consolidation we need.
Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.